Summary & Overview
HCPCS J9119: Injection, cemiplimab-rwlc, 1 mg
HCPCS Level II code J9119 identifies cemiplimab-rwlc billed per milligram and is used when recording administration of this oncology biologic. As a unit-based drug code, it matters nationally for drug utilization tracking, reimbursement for infused or injected cancer therapies, and cost forecasting for payers and providers. Accurate use of this code affects pharmacy billing, clinical documentation, and claims processing for high-cost immunotherapy agents.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise review of the code’s clinical role, typical sites where the drug is administered, and what to expect in claims workflows. The publication provides benchmarks for unit-based billing, notes common scenarios that drive utilization, and summarizes policy considerations relevant to national payers and Medicare coverage frameworks.
The analysis highlights: how J9119 is applied in outpatient infusion and office settings; implications for claim line itemization and per-milligram billing; variations payers commonly apply to reimbursement and utilization management; and points of attention for accurate charge capture. Data not available in the input includes detailed payer-specific rates, associated ICD-10 diagnosis pairings, and related code crosswalks.
Billing Code Overview
HCPCS Level II code J9119 represents an injectable oncology medication: injection, cemiplimab-rwlc, 1 mg. This code describes the drug product and a per-milligram billing unit for administration of cemiplimab-rwlc.
Service Type: Drug administration (intravenous infusion or injection) — oncology/infusion therapy
Typical Site of Service: Hospital outpatient infusion center, physician office infusion suite, or dedicated oncology clinic
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with locally advanced or metastatic cutaneous squamous cell carcinoma or another FDA-approved indication receiving intravenous immunotherapy with cemiplimab-rwlc. The patient presents to an oncology infusion center or outpatient hospital infusion clinic for administration. Pre-infusion workflow includes verification of the order for J9119 (cemiplimab-rwlc, 1 mg), review of baseline labs (complete blood count, comprehensive metabolic panel), assessment for active infections, documentation of prior immune-related adverse events, and confirmation of the intended dosing regimen and body weight per the prescribing information. During the encounter, a licensed registered nurse or infusion pharmacist prepares the dose, obtains vascular access (peripheral IV or implanted port), administers the drug over the required infusion time, and monitors for infusion-related and immune-mediated adverse reactions. Post-infusion workflow includes observation for immediate reactions, documentation of lot number and units administered, patient education on delayed immune-related effects, and scheduling follow-up oncology visits and subsequent infusions according to the treatment plan.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier used/standard reporting | Use when no other modifier applies and standard single-service reporting is required |